Last Updated: May 2026
Cartalax is a synthetic tripeptide (Ala-Glu-Asp) from the Khavinson bioregulator family, researched for cartilage-targeted bioregulation, joint tissue support, and connective tissue function. It is one of the synthesized Khavinson compounds with a defined three-amino-acid sequence. Cartalax is not approved by the FDA, EMA, or any major Western regulator and is sold as a research-use-only compound by third-party laboratories.
Cartalax is a synthetic Ala-Glu-Asp tripeptide proposed to enter chondrocyte and connective-tissue cell nuclei and modulate gene expression in pathways related to cartilage matrix production, chondrocyte maintenance, and joint tissue homeostasis. Within the Khavinson framework, Cartalax is positioned as the cartilage-targeted bioregulator complement to organ-specific peptides like Cardiogen (cardiac) and Vesugen (vascular). Preclinical work has reported effects on collagen synthesis and chondrocyte function markers in cell culture models. Evidence level: Preclinical (cell culture, limited rodent); Khavinson-group research; independent replication limited.
Preclinical studies from the Khavinson group have reported effects on chondrocyte function, collagen synthesis markers, and cartilage matrix production in cell culture models. Human clinical research at FDA-grade Phase 2/3 standards has not been conducted. Russian clinical use has been reported in osteoarthritis and joint-recovery contexts as part of broader bioregulator protocols. Evidence level: Preclinical (cell culture); Khavinson-group research; FDA-grade Phase 2/3 not conducted.
Cartalax targets connective tissue (cartilage), distinguishing it within the Khavinson cluster where most compounds target single-organ systems. Its sequence and structure follow the standard Khavinson tripeptide pattern.
| Bioregulator | Structure | Target tissue | Primary research focus |
|---|---|---|---|
| Cartalax | Tripeptide (Ala-Glu-Asp) | Cartilage / connective tissue | Joint, matrix production |
| Cardiogen | Tetrapeptide (Ala-Glu-Asp-Arg) | Cardiac | Myocardial function |
| Pinealon | Tripeptide (Glu-Asp-Arg) | Pineal / brain | Neuroprotection |
| Vesugen | Tripeptide (Lys-Glu-Asp) | Vascular | Endothelial function |
Side effects in available preclinical data and community-reported research use are mild — injection-site reactions are the most common report. The Khavinson bioregulator class as a whole has a favorable safety profile in available data. Long-term safety in humans at sustained research-use dosing is not characterized at Western clinical standards. Evidence level: Preclinical safety; human long-term unestablished.
Cartalax is not approved by the FDA, EMA, or any major Western regulator as of May 2026. It is used in Russian clinical and research contexts as part of Khavinson-framework protocols. Regulatory context in FDA peptide regulation 2025–2026 timeline.
Cartalax shares structural similarity with several other Khavinson tripeptides — Ala-Glu-Asp varies from other tripeptides in the cluster by single amino acid substitutions — making mass spectrometry identity confirmation important to verify the correct sequence. Independent HPLC purity testing is the standard quality signal. Guidance in how-to-test-peptides hub.
Peptigrity purchases Cartalax vials anonymously at standard customer pricing, sends them to ISO-accredited third-party labs for HPLC and mass spectrometry analysis, and publishes the unedited certificate of analysis. Methodology in how we calculate trust scores.
Cartalax is proposed to act on cartilage and connective tissue through epigenetic gene-expression modulation, with preclinical research focused on chondrocyte function, collagen synthesis, and cartilage matrix production. Human Phase 2/3 efficacy is not established at Western clinical standards.
Cartalax is legal to purchase as a research chemical for laboratory use in most jurisdictions, but it is not approved for human consumption in the US, EU, or most Western markets. Country breakdown in peptide legal status guide.
No active FDA approval pathway exists for Cartalax as of May 2026.
Independent third-party HPLC certificate of analysis from a lab the vendor does not own or pay, with mass spectrometry identity confirmation. Mass spec is essential because Cartalax shares amino acid composition with other Khavinson tripeptides. COA interpretation in red flags in peptide certificates of analysis.
No. Cartalax is not approved for human consumption in Western jurisdictions and Peptigrity is an independent review platform, not a medical authority. Anyone considering use should consult a licensed physician.
Different mechanism families — Cartalax operates through proposed epigenetic gene-expression modulation in connective tissue; BPC-157 is a 15-amino-acid peptide proposed to act through angiogenesis, growth-factor signaling, and tissue-repair pathways. They are not interchangeable; BPC-157 has substantially more independent research support, while Cartalax has Khavinson-framework theoretical positioning specific to cartilage.
This section is for educational and informational purposes only and does not constitute medical advice. Cartalax is not approved by the FDA or any major Western regulator for human use. Always consult a qualified healthcare provider before using any peptide or research compound. Peptigrity is an independent review platform and does not sell, endorse, or recommend specific products or vendors.
Real protocols and questions from members — independent of vendors, never sponsored.
Sign in to ask a question.
Every submitted test helps the community verify purity across brands. Free, fast, independent.